首页 > 最新文献

Acta gastro-enterologica Belgica最新文献

英文 中文
Respiratory failure in a tofacitinib treated patient with ulcerative colitis. 一名接受托法替尼治疗的溃疡性结肠炎患者出现呼吸衰竭。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.11812
C Bosteels, M Truyens, Y Vande Weygaerde, T Malfait, S Libbrecht, L Ferdinande, J Geldof, T Lobaton
{"title":"Respiratory failure in a tofacitinib treated patient with ulcerative colitis.","authors":"C Bosteels, M Truyens, Y Vande Weygaerde, T Malfait, S Libbrecht, L Ferdinande, J Geldof, T Lobaton","doi":"10.51821/87.2.11812","DOIUrl":"https://doi.org/10.51821/87.2.11812","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"336-339"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A giant Brunner's gland hamartoma: a rare cause of upper gastrointestinal bleeding. 巨型布鲁氏腺瘤:上消化道出血的罕见病因。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12806
I Mendes, F Vara-Luiz, G Nunes, J Cruz, S C Antunes, J Fonseca
{"title":"A giant Brunner's gland hamartoma: a rare cause of upper gastrointestinal bleeding.","authors":"I Mendes, F Vara-Luiz, G Nunes, J Cruz, S C Antunes, J Fonseca","doi":"10.51821/87.2.12806","DOIUrl":"https://doi.org/10.51821/87.2.12806","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"340"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Essential reading from the editor's desk. 编辑桌上的必读书目。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.13460
C Reenaers, H De Schepper
{"title":"Essential reading from the editor's desk.","authors":"C Reenaers, H De Schepper","doi":"10.51821/87.2.13460","DOIUrl":"https://doi.org/10.51821/87.2.13460","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"221-222"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection. 抗核苷酸血清学阳性或有 COVID-19 感染史的炎症性肠病患者的 SARS-CoV-2 抗体疫苗反应。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12805
A Hoyois, C Gulkilik, L Mekkaoui, H Dahma, V Wambacq, C Minsart, N Rosewick, C Liefferinckx, L Amininejad, A Van Gossum, A Cremer, O Vandenberg, D Franchimont

Background: Previous history of COVID-19 infection is a natural booster of the vaccine response in the general population. The response to COVID-19 vaccines is lessened in Inflammatory Bowel Disease patients on selected class of immunosuppressive treatments.

Aims: The study was to assess anti-SARS-CoV-2 spike-specific IgG antibody response in Inflammatory Bowel Disease patients with a history of COVID-19 infection.

Patients and methods: This single-center prospective study involved 504 Inflammatory Bowel Disease patients. Demographic data and clinical data were gathered through questionnaires and patient charts. Anti-SARS-CoV-2 spike-specific and antinucleocapsid antibody levels were measured at T1, T2 (after the 2-dose series), and T3 or T4 (booster vaccine).

Results: This study included 504 Inflammatory Bowel Disease patients, and 234 completed one year follow-up with blood tests. Positive anti-nucleocapsid serology or history of COVID-19 infection was significantly associated with increased median anti- SARS-CoV-2 spike-specific IgG titers after the 2-dose series (1930 BAU/mL vs. 521 BAU/mL p < 0.0001) and the booster vaccine (4390 BAU/mL vs. 2160 BAU/mL, p = 0.0156). Multivariate analysis showed that higher anti-SARS-CoV-2 spike-specific IgG levels were independently associated with anti-nucleocapsid antibodies at T2 (OR=2.23, p < 0.0001) and T3 (OR=1.72, p = 0.00011). Immunosuppressive treatments did not impact the antibody response or levels in patients with a history of COVID-19 infection or positive anti-nucleocapsid serology.

Conclusions: In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.

背景:在普通人群中,既往的 COVID-19 感染史会自然增强疫苗反应。目的:该研究旨在评估有 COVID-19 感染史的炎症性肠病患者的抗 SARS-CoV-2 棘突特异性 IgG 抗体反应:这项单中心前瞻性研究涉及 504 名炎症性肠病患者。通过问卷调查和病历收集了人口统计学数据和临床数据。在T1、T2(2剂系列疫苗接种后)、T3或T4(加强疫苗接种后)测定抗SARS-CoV-2尖峰特异性抗体和抗核苷酸抗体水平:这项研究包括 504 名炎性肠病患者,其中 234 人完成了为期一年的血液检测随访。抗核头状病毒血清学阳性或 COVID-19 感染史与两剂系列疫苗(1930 BAU/mL 对 521 BAU/mL,p < 0.0001)和加强疫苗(4390 BAU/mL 对 2160 BAU/mL,p = 0.0156)后抗 SARS-CoV-2 穗特异性 IgG 滴度中位数升高有显著相关性。多变量分析显示,较高的抗SARS-CoV-2尖峰特异性IgG水平与T2(OR=2.23,p < 0.0001)和T3(OR=1.72,p = 0.00011)的抗核头抗体独立相关。免疫抑制治疗不会影响有COVID-19感染史或抗核苷酸血清学阳性患者的抗体反应或水平:结论:在炎症性肠病患者中,无论免疫抑制治疗与否,接种疫苗后,COVID-19感染史或抗核苷酸血清学阳性会导致抗SARS-CoV-2尖峰特异性IgG水平升高。这强调了在疫苗接种方法中考虑既往感染的重要性。
{"title":"SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.","authors":"A Hoyois, C Gulkilik, L Mekkaoui, H Dahma, V Wambacq, C Minsart, N Rosewick, C Liefferinckx, L Amininejad, A Van Gossum, A Cremer, O Vandenberg, D Franchimont","doi":"10.51821/87.2.12805","DOIUrl":"10.51821/87.2.12805","url":null,"abstract":"<p><strong>Background: </strong>Previous history of COVID-19 infection is a natural booster of the vaccine response in the general population. The response to COVID-19 vaccines is lessened in Inflammatory Bowel Disease patients on selected class of immunosuppressive treatments.</p><p><strong>Aims: </strong>The study was to assess anti-SARS-CoV-2 spike-specific IgG antibody response in Inflammatory Bowel Disease patients with a history of COVID-19 infection.</p><p><strong>Patients and methods: </strong>This single-center prospective study involved 504 Inflammatory Bowel Disease patients. Demographic data and clinical data were gathered through questionnaires and patient charts. Anti-SARS-CoV-2 spike-specific and antinucleocapsid antibody levels were measured at T1, T2 (after the 2-dose series), and T3 or T4 (booster vaccine).</p><p><strong>Results: </strong>This study included 504 Inflammatory Bowel Disease patients, and 234 completed one year follow-up with blood tests. Positive anti-nucleocapsid serology or history of COVID-19 infection was significantly associated with increased median anti- SARS-CoV-2 spike-specific IgG titers after the 2-dose series (1930 BAU/mL vs. 521 BAU/mL p < 0.0001) and the booster vaccine (4390 BAU/mL vs. 2160 BAU/mL, p = 0.0156). Multivariate analysis showed that higher anti-SARS-CoV-2 spike-specific IgG levels were independently associated with anti-nucleocapsid antibodies at T2 (OR=2.23, p < 0.0001) and T3 (OR=1.72, p = 0.00011). Immunosuppressive treatments did not impact the antibody response or levels in patients with a history of COVID-19 infection or positive anti-nucleocapsid serology.</p><p><strong>Conclusions: </strong>In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"263-273"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thinking outside the box in lower gastrointestinal bleeding. 下消化道出血的新思路。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12781
M J Temido, E Gravito-Soares, M Gravito-Soares, P Figueiredo
{"title":"Thinking outside the box in lower gastrointestinal bleeding.","authors":"M J Temido, E Gravito-Soares, M Gravito-Soares, P Figueiredo","doi":"10.51821/87.2.12781","DOIUrl":"10.51821/87.2.12781","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"349-350"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest? 代谢功能障碍相关脂肪性肝病:隐藏在森林中的树木?
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.13087
G Henin, P Baldin, C Frans, V Havelange, B Delire, J C Yombi, N Lanthier
{"title":"Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest?","authors":"G Henin, P Baldin, C Frans, V Havelange, B Delire, J C Yombi, N Lanthier","doi":"10.51821/87.2.13087","DOIUrl":"10.51821/87.2.13087","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"344-345"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bismuth-based quadruple therapy versus standard triple therapy for the eradication of Helicobacter pylori in Belgium: a multicentre, non-blinded randomized, prospective study. 比利时根除幽门螺杆菌的铋剂四联疗法与标准三联疗法:一项多中心、非盲法随机前瞻性研究。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12142
S François, F Mana, R Ntounda, V Lamy, S Cadranel, P Bontems, V Miendje Deyi, E Macken, S Kindt

Background: Helicobacter pylori (Hp) infection predisposes to malignant and non-malignant diseases warranting eradication. In Belgium, resistance rates for clarithromycin demonstrate regional variations making the use of standard triple therapy (STT) borderline acceptable. According to a recent Belgian survey, STT and bismuth-based quadruple therapy (BQT), are equally frequent prescribed as first line treatment for treatment naïve Hp positive patients. This study aims to evaluate the eradication rates (ER) of BQT versus STT.

Methods: Multicentre, non-blinded randomized, prospective study comparing ER in treatment-naïve Hp positive patients. ER were compared by intention to treat (ITT) and per protocol (PP) analysis.

Results: Overall 250 patients were included (STT 126, BQT 124). Seventeen patients were lost to follow-up (6,8%). No significant difference in ER between BQT and STT was observed in ITT (73% vs 68%, p= 0,54) neither in PP analysis (81% vs 75%, p= 0,33). Side effects and endoscopic findings were comparable between groups. Post-hoc analysis showed no differences according to gender or site allocation.

Conclusion: The numerical advantage of BQT did not translate in a significant improvement of ER when compared with STT. These results question the cost-effectiveness of BQT, while confirming the suboptimal eradication rates on STT. A nationwide monitoring of resistance patterns, maximal investments in treatment adherence as well as a detailed follow-up of the changing treatment landscape are mandatory to continuously optimise Hp ER in Belgium.

背景:幽门螺杆菌(Hp)感染易导致恶性和非恶性疾病,因此必须根除。在比利时,克拉霉素的耐药率存在地区差异,这使得使用标准三联疗法(STT)成为可接受的边缘疗法。根据比利时最近的一项调查,标准三联疗法和铋剂四联疗法(BQT)作为一线疗法用于治疗Hp阳性患者的频率相同。本研究旨在评估 BQT 与 STT 的根除率(ER):多中心、非盲法、随机、前瞻性研究,比较对 Hp 阳性患者的根除率。通过意向治疗(ITT)和按方案(PP)分析比较ER:共纳入 250 名患者(STT 126 人,BQT 124 人)。17名患者失去了随访机会(6.8%)。在 ITT(73% vs 68%,P= 0.54)和 PP 分析(81% vs 75%,P= 0.33)中,BQT 和 STT 的 ER 均无明显差异。各组的副作用和内窥镜检查结果相当。事后分析表明,性别和手术部位分配无差异:结论:与 STT 相比,BQT 在数字上的优势并不能显著改善 ER。这些结果对 BQT 的成本效益提出了质疑,同时也证实了 STT 的根除率并不理想。要持续优化比利时的 Hp ER,就必须在全国范围内对抗药性模式进行监测,对坚持治疗进行最大程度的投资,并对不断变化的治疗情况进行详细跟踪。
{"title":"Bismuth-based quadruple therapy versus standard triple therapy for the eradication of Helicobacter pylori in Belgium: a multicentre, non-blinded randomized, prospective study.","authors":"S François, F Mana, R Ntounda, V Lamy, S Cadranel, P Bontems, V Miendje Deyi, E Macken, S Kindt","doi":"10.51821/87.2.12142","DOIUrl":"10.51821/87.2.12142","url":null,"abstract":"<p><strong>Background: </strong>Helicobacter pylori (Hp) infection predisposes to malignant and non-malignant diseases warranting eradication. In Belgium, resistance rates for clarithromycin demonstrate regional variations making the use of standard triple therapy (STT) borderline acceptable. According to a recent Belgian survey, STT and bismuth-based quadruple therapy (BQT), are equally frequent prescribed as first line treatment for treatment naïve Hp positive patients. This study aims to evaluate the eradication rates (ER) of BQT versus STT.</p><p><strong>Methods: </strong>Multicentre, non-blinded randomized, prospective study comparing ER in treatment-naïve Hp positive patients. ER were compared by intention to treat (ITT) and per protocol (PP) analysis.</p><p><strong>Results: </strong>Overall 250 patients were included (STT 126, BQT 124). Seventeen patients were lost to follow-up (6,8%). No significant difference in ER between BQT and STT was observed in ITT (73% vs 68%, p= 0,54) neither in PP analysis (81% vs 75%, p= 0,33). Side effects and endoscopic findings were comparable between groups. Post-hoc analysis showed no differences according to gender or site allocation.</p><p><strong>Conclusion: </strong>The numerical advantage of BQT did not translate in a significant improvement of ER when compared with STT. These results question the cost-effectiveness of BQT, while confirming the suboptimal eradication rates on STT. A nationwide monitoring of resistance patterns, maximal investments in treatment adherence as well as a detailed follow-up of the changing treatment landscape are mandatory to continuously optimise Hp ER in Belgium.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"235-240"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different aspects of immunological profile in patients with Non-Alcoholic Fatty liver disease. 非酒精性脂肪肝患者免疫特征的不同方面。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12205
H A Osman, M Tag-Adeen, U M Abdelaal, E Elgezawy, K A Nasif, A Nafady

Background: NAFLD is thought to affect approximately one-fourth of the world's population. Therefore, we evaluated the role of serum complement and immunoglobulins in the NAFLD pathogenesis.

Patients and methods: 200 participants were used in this study, divided into two groups; Group I: 100 NAFLD patients and Group II: 100 healthy volunteers. The diagnosis of NAFLD is based on non-invasive methods, following the EASL guideline 2022. IgG, IgM, IgA, C3, and C4 assays were performed on all participants.

Results: When the immunological profiles of patients with NAFLD and healthy controls were compared, it was found that the mean IgA in NAFLD patients was (4.20±5.07), whereas the mean IgA in healthy controls was (2.22±1.05) (P=0.000). Additionally, a significant increase in IgG was found in NAFLD patients (17.08±3.87) compared with healthy controls (11.59±3.34), with a P value of (p<0.001). complement C3 and complement C4 levels significantly increased in nonalcoholic fatty liver disease patients (1.28± 0.61 and 0.40 ± 0.19, respectively), compared to healthy controls (0.90 ±0.27 and 0.30 ±0.12, respectively), with a significant P value (p<0.001 for each).

Conclusions: Elevated IgA, IgG, C3 and C4 exist in patients with NAFLD and could be associated with fatty liver development and progression of hepatic fibrosis in patients with NAFLD.

背景:非酒精性脂肪肝被认为影响着全球约四分之一的人口。因此,我们对血清补体和免疫球蛋白在非酒精性脂肪肝发病机制中的作用进行了评估。患者和方法:本研究有 200 名参与者,分为两组:第一组:100 名非酒精性脂肪肝患者;第二组:100 名健康志愿者。非酒精性脂肪肝的诊断基于非侵入性方法,遵循 EASL 指南 2022。对所有参与者进行了 IgG、IgM、IgA、C3 和 C4 检测:比较非酒精性脂肪肝患者和健康对照组的免疫学特征,发现非酒精性脂肪肝患者的平均 IgA 为(4.20±5.07),而健康对照组的平均 IgA 为(2.22±1.05)(P=0.000)。此外,与健康对照组(11.59±3.34)相比,非酒精性脂肪肝患者的 IgG(17.08±3.87)明显增加,P 值为(P结论:非酒精性脂肪肝患者的 IgA、IgG、C3 和 C4 升高,可能与非酒精性脂肪肝患者脂肪肝的发展和肝纤维化的进展有关。
{"title":"Different aspects of immunological profile in patients with Non-Alcoholic Fatty liver disease.","authors":"H A Osman, M Tag-Adeen, U M Abdelaal, E Elgezawy, K A Nasif, A Nafady","doi":"10.51821/87.2.12205","DOIUrl":"https://doi.org/10.51821/87.2.12205","url":null,"abstract":"<p><strong>Background: </strong>NAFLD is thought to affect approximately one-fourth of the world's population. Therefore, we evaluated the role of serum complement and immunoglobulins in the NAFLD pathogenesis.</p><p><strong>Patients and methods: </strong>200 participants were used in this study, divided into two groups; Group I: 100 NAFLD patients and Group II: 100 healthy volunteers. The diagnosis of NAFLD is based on non-invasive methods, following the EASL guideline 2022. IgG, IgM, IgA, C3, and C4 assays were performed on all participants.</p><p><strong>Results: </strong>When the immunological profiles of patients with NAFLD and healthy controls were compared, it was found that the mean IgA in NAFLD patients was (4.20±5.07), whereas the mean IgA in healthy controls was (2.22±1.05) (P=0.000). Additionally, a significant increase in IgG was found in NAFLD patients (17.08±3.87) compared with healthy controls (11.59±3.34), with a P value of (p<0.001). complement C3 and complement C4 levels significantly increased in nonalcoholic fatty liver disease patients (1.28± 0.61 and 0.40 ± 0.19, respectively), compared to healthy controls (0.90 ±0.27 and 0.30 ±0.12, respectively), with a significant P value (p<0.001 for each).</p><p><strong>Conclusions: </strong>Elevated IgA, IgG, C3 and C4 exist in patients with NAFLD and could be associated with fatty liver development and progression of hepatic fibrosis in patients with NAFLD.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"274-281"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial chylomicronemia syndrome: a novel mutation in the lipoprotein lipase gene. 家族性乳糜微粒血症综合征:脂蛋白脂肪酶基因的新型突变。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12025
S Van Biervliet, S Vande Velde, P De Bruyne, B Callewaert, P Verloo, R De Bruyne
{"title":"Familial chylomicronemia syndrome: a novel mutation in the lipoprotein lipase gene.","authors":"S Van Biervliet, S Vande Velde, P De Bruyne, B Callewaert, P Verloo, R De Bruyne","doi":"10.51821/87.2.12025","DOIUrl":"10.51821/87.2.12025","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"326-328"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute grade IV toxic hepatitis due to the e-cigarette. 电子烟导致急性 IV 级中毒性肝炎。
IF 1.5 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 DOI: 10.51821/87.1.11378
G Van Roey, W Goos, C Claessens, A Hoorens, W Verlinden, J Schouten

A 46-year-old woman presented at the emergency department because of acute hepatitis with jaundice. After hepatological work-up including liver biopsy, drug induced liver disease (DILI) was suspected. Patient recovered completely within a few months. One year later she presented again with jaundice due to acute hepatitis. Vaping was the only agent that could be identified as causative agent for DILI. After VAPING cessation, the hepatitis resolved completely. Calculated RUCAM score was 10, making the diagnosis of toxic hepatitis very likely. During follow-up liver tests remained normal. This is the first report of severe DILI secondary to the use of e-cigarettes. In future vaping can be included in the differential diagnosis of DILI.

一名 46 岁的女性因急性肝炎伴黄疸型肝炎到急诊科就诊。经过包括肝活检在内的肝脏检查,怀疑是药物性肝病(DILI)。患者在几个月内完全康复。一年后,她因急性肝炎再次出现黄疸。吸食毒品是唯一可以确定导致 DILI 的致病因素。停止吸烟后,肝炎完全痊愈。计算的 RUCAM 评分为 10 分,诊断为中毒性肝炎的可能性非常大。随访期间,肝脏化验结果保持正常。这是首例因使用电子烟而继发严重 DILI 的报告。今后可将电子烟纳入 DILI 的鉴别诊断中。
{"title":"Acute grade IV toxic hepatitis due to the e-cigarette.","authors":"G Van Roey, W Goos, C Claessens, A Hoorens, W Verlinden, J Schouten","doi":"10.51821/87.1.11378","DOIUrl":"10.51821/87.1.11378","url":null,"abstract":"<p><p>A 46-year-old woman presented at the emergency department because of acute hepatitis with jaundice. After hepatological work-up including liver biopsy, drug induced liver disease (DILI) was suspected. Patient recovered completely within a few months. One year later she presented again with jaundice due to acute hepatitis. Vaping was the only agent that could be identified as causative agent for DILI. After VAPING cessation, the hepatitis resolved completely. Calculated RUCAM score was 10, making the diagnosis of toxic hepatitis very likely. During follow-up liver tests remained normal. This is the first report of severe DILI secondary to the use of e-cigarettes. In future vaping can be included in the differential diagnosis of DILI.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 1","pages":"44-47"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140020731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta gastro-enterologica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1